Want to see AU:VBS full AI Analyst Report?
Top Page
Vectus Biosystems Limited
(Sydney:VBS)
Select Model
Select Model
Rating:48Neutral
Price Target:
AU$0.13
â–Ľ(-28.33% Downside)
Action:Reiterated
Date:07/16/26
The score is held down primarily by weak financial performance (shrinking revenue, persistent losses, ongoing cash burn, and a move to negative equity that increases funding risk). Technicals provide partial support with the stock trading above major moving averages and a positive MACD, but overbought RSI/Stoch readings reduce the technical score. Valuation is also constrained because the company is loss-making (negative P/E) and no dividend yield is available.
Positive Factors
High gross margins
A consistently very high gross margin profile provides durable unit economics: once revenue stabilizes, gross profits can cover fixed R&D and G&A. Over the medium term this supports scalable margin expansion and gives management leverage to prioritize profitable product lines or partnerships.
Negative Factors
Shrinking revenue
A 45.9% revenue decline is a structural red flag: it erodes scale, weakens pricing leverage, and increases per-unit fixed cost absorption. Over several quarters this trend materially lengthens the path to breakeven, undermines investor confidence, and raises the likelihood of repeated capital raises.
Read all positive and negative factors
Positive Factors
Negative Factors
High gross margins
A consistently very high gross margin profile provides durable unit economics: once revenue stabilizes, gross profits can cover fixed R&D and G&A. Over the medium term this supports scalable margin expansion and gives management leverage to prioritize profitable product lines or partnerships.
Read all positive factors
Vectus Biosystems Limited (VBS) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$9.90M
Dividend YieldN/A
Average Volume (3M)97.35K
Price to Earnings (P/E)―
Beta (1Y)1.05
Revenue GrowthN/A
EPS Growth37.88%
CountryAU
Employees5
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.03
Shares Outstanding61,867,050
10 Day Avg. Volume169,215
30 Day Avg. Volume97,349
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)-8.29
Price to Sales (P/S)4.45
P/FCF Ratio-2.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Vectus Biosystems Limited Business Overview & Revenue Model
Company Description
Vectus Biosystems Limited, an Australian medical research and development firm, specializes in devising therapies for fibrotic conditions and hypertension. Its pharmaceutical pipeline addresses ailments affecting the heart, kidneys, liver, and lun...
How the Company Makes Money
null...
Vectus Biosystems Limited Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
22
Negative
Cash Flow
17
Very Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 84.47K | 478.18K | 1.14M | 1.35M | 1.30M | 180.00 |
| Gross Profit | 82.89K | 478.18K | 1.14M | 1.31M | 1.28M | 1.02M |
| EBITDA | -1.39M | -1.69M | -2.27M | -3.19M | -3.28M | -3.71M |
| Net Income | -1.41M | -1.78M | -2.34M | -3.45M | -3.99M | -3.86M |
Balance Sheet | ||||||
| Total Assets | 461.65K | 782.66K | 2.03M | 4.63M | 3.94M | 6.98M |
| Cash, Cash Equivalents and Short-Term Investments | 330.50K | 250.99K | 808.97K | 2.95M | 1.28M | 5.78M |
| Total Debt | 467.10K | 200.00K | 28.93K | 70.21K | 6.90M | 8.68M |
| Total Liabilities | 1.27M | 1.04M | 539.26K | 1.11M | 8.36M | 9.88M |
| Stockholders Equity | -806.29K | -256.62K | 1.49M | 3.52M | -4.42M | -2.90M |
Cash Flow | ||||||
| Free Cash Flow | -830.47K | -830.09K | -2.10M | -2.37M | -4.46M | -3.26M |
| Operating Cash Flow | -830.47K | -830.09K | -2.03M | -2.35M | -4.44M | -3.26M |
| Investing Cash Flow | -70.00K | 101.03K | -67.90K | -17.13K | -21.00K | 0.00 |
| Financing Cash Flow | 421.07K | 171.07K | -41.28K | 4.04M | -34.55K | 6.35M |
Vectus Biosystems Limited Technical Analysis
Positive
0.18
Price Trends
0.15
Positive
0.14
Positive
0.15
Positive
Market Momentum
<0.01
Negative
57.36
Neutral
75.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:VBS, the sentiment is Positive. The current price of 0.18 is above the 20-day moving average (MA) of 0.15, above the 50-day MA of 0.15, and above the 200-day MA of 0.15, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 57.36 is Neutral, neither overbought nor oversold. The STOCH value of 75.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:VBS.
Vectus Biosystems Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | AU$9.90M | -6.06 | 265.12% | ― | ― | 37.88% | |
48 Neutral | AU$60.21M | -0.47 | -131.13% | ― | 2086.71% | -116.20% | |
46 Neutral | AU$5.14M | -1.34 | -29.91% | ― | 82.28% | 13.33% | |
46 Neutral | AU$10.60M | -2.03 | -161.62% | ― | 76.94% | 42.95% | |
41 Neutral | AU$215.14M | -15.13 | -44.80% | ― | 49.03% | -232.68% | |
40 Underperform | AU$5.90M | -1.72 | -211.88% | ― | 250.37% | 71.29% |
* Healthcare Sector Average
AU:VBS
Vectus Biosystems Limited
0.16
0.09
142.42%
AU:ACR
Acrux
0.01
>-0.01
-28.57%
AU:OCC
Orthocell Ltd
0.77
-0.56
-42.11%
AU:TRP
Tissue Repair Ltd
0.09
-0.20
-69.64%
AU:CMB
Regeneus Ltd.
0.36
-0.01
-2.70%
AU:BOT
Botanix Pharmaceuticals Limited
0.02
-0.13
-85.33%
Vectus Biosystems Limited Corporate Events
Vectus Biosystems Issues New Shares Under Employee Incentive Plan
Jul 29, 2026
Vectus Biosystems has issued 176,703 new fully paid ordinary shares following the exercise of employee options under its incentive plan. The bulk of the allocation, 163,500 shares, went to Chief Executive Officer and Chief Technology Officer Dr Ta...
Vectus Biosystems Seeks ASX Quotation for Additional Ordinary Shares
Jul 29, 2026
Vectus Biosystems Limited has applied for the quotation of 176,703 new ordinary fully paid shares on the ASX, with an issue date of July 29, 2026. The additional securities, arising from the exercise or conversion of existing instruments, will mod...
Vectus Biosystems bolsters leadership, funding and U.S. regulatory push for fibrosis pipeline
Jul 28, 2026
Vectus Biosystems has strengthened its leadership by appointing Dr Tara Speranza as Chief Executive Officer and Chief Technology Officer, leveraging her extensive experience in scientific research, drug development and capital markets to support t...
Vectus Biosystems Appoints U.S. Regulatory Agent to Advance IPF Drug VB0004
Jul 13, 2026
Vectus Biosystems has appointed Cardinal Health Regulatory Services as its U.S. Regulatory Agent to manage all Food and Drug Administration interactions for its lead compound, VB0004, including orphan drug designation, pre-IND discussions and the ...
Vectus Biosystems issues new shares to CEO under incentive plan
Jun 26, 2026
Vectus Biosystems Limited has issued 196,200 new fully paid ordinary shares to its Chief Executive Officer and Chief Technology Officer, Dr Tara Speranza, following the exercise of options granted under the company’s Employee Incentive Plan ...
Vectus Biosystems Lists Additional Shares on ASX
Jun 26, 2026
Vectus Biosystems Limited has applied for the quotation of 196,200 new ordinary fully paid shares on the Australian Securities Exchange, with an issue date of 26 June 2026. The additional securities, arising from exercised options or converted ins...
Vectus Biosystems’ New CEO to Outline Antifibrotic Strategy in Investor Webinar
Jun 16, 2026
Vectus Biosystems will host an investor webinar on 23 June 2026, led by newly appointed CEO and CTO Dr Tara Speranza, to outline the company’s refreshed strategic direction and near-term priorities. The session will cover plans to advance it...
Vectus Biosystems Raises $791,000 to Accelerate VB0004 Clinical Trial
May 27, 2026
Vectus Biosystems Limited has raised $791,000 through the issue of 7,910,000 new fully paid ordinary shares to sophisticated investors at $0.10 per share under a recently announced placement. The funds will be directed primarily to accelerating th...
Vectus Biosystems Seeks ASX Quotation for 7.9 Million New Shares
May 27, 2026
Vectus Biosystems Limited has applied to the ASX for quotation of 7,910,000 new ordinary fully paid shares, with an issue date of 27 May 2026. The move formalises the listing of securities previously flagged to the market, potentially broadening t...
Vectus Biosystems Plans Share and Option Issue to Raise Capital
May 22, 2026
Vectus Biosystems Limited has lodged an Appendix 3B outlining a proposed placement or similar issue of new securities on the ASX. The company plans to issue up to 7,910,000 ordinary fully paid shares and an equal number of options exercisable at $...
Vectus Biosystems Raises Capital to Accelerate VB0004 Fibrosis Trials
May 22, 2026
Vectus Biosystems has raised approximately $0.8 million through a placement of 7.91 million new shares at $0.10 each to institutional and sophisticated investors, with attaching options subject to shareholder approval. The capital will strengthen ...
Vectus Biosystems to List Additional Shares on ASX After Option Conversions
May 12, 2026
Vectus Biosystems Limited has applied to the ASX for quotation of 41,817 new ordinary fully paid shares, to be issued on 12 May 2026. The additional securities arise from the exercise or conversion of existing options or other convertible instrume...
Vectus Biosystems Issues New Shares Linked to Executive Appointment
May 8, 2026
Vectus Biosystems has issued 109,000 new fully paid ordinary shares as part of the employment agreement for its newly appointed Chief Executive Officer and Chief Technology Officer, Dr Tara Speranza. The move signals a strengthening of the company...
Vectus Biosystems issues new shares to incoming CEO-CTO
May 8, 2026
Vectus Biosystems has applied to the ASX for quotation of 109,000 new fully paid ordinary shares, issued to its newly appointed Chief Executive Officer and Chief Technology Officer, Dr Tara Speranza. The share grant, made under the terms of her em...
Vectus Biosystems Grants 981,000 Unquoted Options Under Employee Scheme
May 8, 2026
Vectus Biosystems Limited has issued 981,000 unquoted options under its employee incentive scheme, with no consideration payable on exercise. These options, which will not be quoted on the ASX, are designed to reward and retain staff, signalling t...
Vectus Biosystems names Dr Tara Speranza CEO and CTO to drive next growth phase
May 7, 2026
Vectus Biosystems has appointed Dr Tara Speranza as both Chief Executive Officer and Chief Technology Officer, formalising a relationship that began with her consulting work in 2025 and leveraging her extensive background in translational drug dev...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.